SELLAS Life Sciences (SLS) Other Non-Current Assets (2010 - 2026)
SELLAS Life Sciences (SLS) reported Other Non-Current Assets of $255000.0 for Q1 2026, down 3.04% year-over-year from $263000.0 in Q1 2025, and down 0.78% quarter-over-quarter from $257000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Other Non-Current Assets (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 17 years of Other Non-Current Assets data on file, last reported at $255000.0 in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $255000.0, down 3.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $255000.0 (down 3.04% YoY), and the FY2025 annual result was $257000.0, down 3.38% from the prior year.
- Other Non-Current Assets fell to $255000.0 in Q1 2026 per SLS's latest filing, from $257000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $554000.0 in Q1 2022 and troughed at $34000.0 in Q3 2025.
- A 5-year average of $313294.1 and a median of $272000.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Assets slumped 88.59% in 2024, then dropped 3.04% in 2026.
- A 5-year view of Other Non-Current Assets shows it stood at $399000.0 in 2022, then tumbled by 31.08% to $275000.0 in 2023, then retreated by 3.27% to $266000.0 in 2024, then slipped by 3.38% to $257000.0 in 2025, then declined by 0.78% to $255000.0 in 2026.
- Business Quant data shows SLS's Other Non-Current Assets at $255000.0 in Q1 2026, $257000.0 in Q4 2025, and $34000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | 255,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 255,000.00 |
| Dec 31, 2025 | 257,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 261,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Dec 31, 2024 | 266,000.00 |
| Sep 30, 2024 | 43,000.00 |
| Jun 30, 2024 | 270,000.00 |
| Mar 31, 2024 | 272,000.00 |
| Dec 31, 2023 | 275,000.00 |
| Sep 30, 2023 | 377,000.00 |
| Jun 30, 2023 | 381,000.00 |
| Mar 31, 2023 | 384,000.00 |
| Dec 31, 2022 | 399,000.00 |
| Sep 30, 2022 | 521,000.00 |
| Jun 30, 2022 | 514,000.00 |
| Mar 31, 2022 | 554,000.00 |
| Dec 31, 2021 | 594,000.00 |
| Sep 30, 2021 | 597,000.00 |
| Jun 30, 2021 | 623,000.00 |